241 related articles for article (PubMed ID: 23818548)
1. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
Kostakoglu L; Gallamini A
J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
Sickinger MT; von Tresckow B; Kobe C; Engert A; Borchmann P; Skoetz N
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010533. PubMed ID: 25572491
[TBL] [Abstract][Full Text] [Related]
3. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
[TBL] [Abstract][Full Text] [Related]
4. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
7. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
Adams HJ; Kwee TC
Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
[TBL] [Abstract][Full Text] [Related]
8. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?
Gallamini A; Kostakoglu L
Blood; 2012 Dec; 120(25):4913-20. PubMed ID: 22932799
[TBL] [Abstract][Full Text] [Related]
9. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
10. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Blood; 2014 Nov; 124(23):3356-64. PubMed ID: 25428223
[TBL] [Abstract][Full Text] [Related]
11. Overview of early response assessment in lymphoma with FDG-PET.
MacManus MP; Seymour JF; Hicks RJ
Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
[TBL] [Abstract][Full Text] [Related]
12. The role of FDG PET in the management of lymphoma: what is the evidence base?
Kirby AM; Mikhaeel NG
Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
[TBL] [Abstract][Full Text] [Related]
13. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
Adams HJ; Kwee TC
Nucl Med Commun; 2016 Dec; 37(12):1333-1334. PubMed ID: 27501435
[No Abstract] [Full Text] [Related]
14. Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging.
Bair SM; Svoboda J
PET Clin; 2019 Jul; 14(3):353-368. PubMed ID: 31084775
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.
Hutchings M; Mikhaeel NG; Fields PA; Nunan T; Timothy AR
Ann Oncol; 2005 Jul; 16(7):1160-8. PubMed ID: 15939713
[TBL] [Abstract][Full Text] [Related]
16. FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.
Lopci E; Mascarin M; Piccardo A; Castello A; Elia C; Guerra L; Borsatti E; Sala A; Todesco A; Zucchetta P; Farruggia P; Cistaro A; Buffardi S; Bertolini P; Bianchi M; Moleti ML; Bunkheila F; Indolfi P; Fagioli F; Garaventa A; Burnelli R;
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):97-106. PubMed ID: 30219963
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
Kostakoglu L; Evens AM
Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
[TBL] [Abstract][Full Text] [Related]
18. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
Adams HJA; Kwee TC
Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
[TBL] [Abstract][Full Text] [Related]
19. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
20. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
Araf S; Montoto S
Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]